Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2468

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2468
---
 strategy enables us to assess and pursue the course that maximizes outcomes for patients and value for our shareholders.

    ●
    Leadership
    team comprised of academic, scientific and business innovators. We have assembled an industry-leading, multi-disciplinary team consisting
    of physicians, scientists and business leaders with significant experience in progressing product candidates from early-stage research
    through clinical trials, regulatory approval and ultimately to commercialization.

12

We
believe our differentiated business model enables us to advance the commercialization of our products, if approved, and will allow us
to replicate our licensing partnerships through aligned incentive structures with research universities and medical centers.

Feeding
our Pipeline: Harnessing Innovations from Research Centers

Our
innovative business model is aimed at translating biomedical inventions from research universities and medical centers into products
that we believe have the potential to dramatically improve patients’ lives. Unlike many biotech companies, our success is not dependent
on any one particular program or disease. Our current pipeline is already well-diversified and our access to innovations from academic
and medical institutions allows us the flexibility to opportunistically develop product candidates, regardless of therapeutic area. We
believe our sources of medical discoveries include not only research universities and medical centers but also companies with assets
that are not core to their business model.

We
use highly selective criteria and stringent due diligence for selecting assets for development. Picking the right assets requires unbiased
and objective science/technology and market assessments that are not affected by institutional legacies, not blinded by research myopia
or academic necessities, and not influenced by “herd mentalities.” We seek to develop technologies that meet our stringent
selection criteria and which are amenable to our controlled de-risking process that we believe can lead to clear and timely value inflection
points and milestones. We intend to keep our focus on projects and technologies that demonstrate clear progress towards becoming commercially
viable products. Our business model aims to diversify our approach away from a single vector of technology research or science, and instead
to pursue a variety of promising research avenues simultaneously and cost effectively. As explained previously, we believe that we can
address the resourcing challenges inherent in such diversity and that the diversity itself is an advantageous business strategy.

Our
model for identifying, structuring and developing assets is based on the following tenets:

    ●
    We
    believe we have a disciplined process for identification, selection and prioritization of programs: We believe that only well-defined
    science can be